AstraZeneca delivers dream result as phase 3 COPD hits breathe life into class rocked by flopsLilly further embraces Insilico’s AI tech, inking R&D collab worth up to $2.75BMerck dives into detailed phase 3 data showing PCSK9 pill easily outswims rivals

AstraZeneca delivers dream result as phase 3 COPD hits breathe life into class rocked by flops Lilly further embraces Insilico’s AI tech, inking R&D collab worth up to $2.75B Merck dives into detailed phase 3 data showing PCSK9 pill easily outswims rivals

AstraZeneca delivers dream result as phase 3 COPD hits breathe life into class rocked by flopsLilly further embraces Insilico’s AI tech, inking R&amp;D collab worth up to $2.75BMerck dives into detailed phase 3 data showing PCSK9 pill easily outswims rivals

Episode#37 Mar 30th 2026: AstraZeneca's IL‑33 Win

A fast paced, AI-generated podcast on pharma and biotech news.

Share Episode#37 Mar 30th 2026: AstraZeneca's IL‑33 Win

Sign up to save your podcasts

Episode#37 Mar 30th 2026: AstraZeneca's IL‑33 Win

Episode#37 Mar 30th 2026: AstraZeneca's IL‑33 Win